1. Company performance:
The company recorded a turnover of about 824 million yuan in 2016, down 16.30% from the same period last year. The profit attributable to the owners of the parent company is about 266 million yuan, down 12% from the same period last year. Profits in the second half of 2016 are basically the same as those in the first half of 2016. The decline in revenue and profit is due to the recovery of Lei Yi's total distribution rights and the recovery of inventory, which is currently being digested.
2. Lei Yi de:
The company has always wanted to recover the general agency, the strength of the distributor is limited, and the agency enterprise has changed. Lei easy handover situation, smooth handover, inventory recovery. Because the shelf life of Lei Yi is 36 months, the original agent has more inventory and longer digestion time.
Only a few provinces failed to apply for Lei's easy tender. Keep 15 provinces winning the bid. There is some pressure on the price.
The company has a long-term goal to take the international route. The international market is being done in Southeast Asia and other countries; the certification of FDA in the United States is also being discussed with foreign enterprises.
3. Lei Yide looks forward to:
Inventory is now fully disposed of and this year is expected to return to 2015 sales levels. In addition, CP's sunny products are also allowed to enter the Hong Kong market, putting some pressure on the company's product sales. The company is currently actively dealing with the response.
4. Research and development:
The company attaches great importance to research and development, currently rich in cash, mainly used for research and development and mergers and acquisitions of good varieties. Consistency evaluation will continue to be done, for each variety. All the varieties at the core of the consistency evaluation should be done, and the company must do the 10 important varieties. The approval of cefmeprazole has been obtained.
5. Esomeprazole:
Proton pump inhibitor esomeprazole after the market sales prospects will be very broad, is an injection, only 2 approved in China, sales will exceed entecavir, AstraZeneca PLC's original drug sales in the domestic scale of several billion.
6. Jieshi Tong:
Approved in 2011, there has been no volume, mainly due to pricing restrictions, health insurance catalogue restrictions.
At present, these factors have been eliminated. Jeston has lifted price restrictions and is waiting to enter provincial health insurance catalogs. It is expected that the quantity will be sold very soon, with a target sales of 1000 million boxes. From the feedback from urologists, the effect is very significant. Phase 4 clinical, plus the indication of gout.
7. Ann Neizhen:
At present, it is mainly sold in retail drugstores, and the price remains ideal. You won't be hit by the price paid by health insurance in the drugstore. This product is very important to the value of the company.
8. Two-vote system:
The two-vote system will have an impact on the company, but it is not big on the whole. The company wins by quality, has been standardizing its operation, and will comply with the regulations. I believe it will be handled very well.
9. Mergers and acquisitions:
The company's current variety is not dominant, the company is strong marketing ability, is the excellent quality of products. Relying on internal endogenous growth, we also have to rely on mergers and acquisitions. At present, we are also paying attention to a number of targets, among which there are more than 1 billion of expired patent drugs acting as agents of multinational corporations. Equity mergers and acquisitions are also being fought for.
10. Summary and suggestions:
The company has better cost control and payback, outstanding product quality, proper bidding strategy, and certain advantages. Lei Yi de has dragged down the company's performance. In the long run, the company takes back the right of distribution, with the company's sales ability, long-term is conducive to the sales of Lei Yi products, but also can improve profit margins, the current medical policy on the price of products under greater pressure, it is recommended to follow up and pay attention.